Patents by Inventor Wenjun Ouyang

Wenjun Ouyang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20230063741
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: April 15, 2022
    Publication date: March 2, 2023
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • INTERLEUKIN-2 IN COMBINATION WITH TNF RECEPTOR FAMILY MEMBERS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20230040604
    Abstract: Provided herein are combinations of an IL-2 molecule or mutein and a TNFR agonist, and complexes comprising IL-2/TNFR agonist molecules, such as Fc-bound IL-2/TNFR agonist molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 9, 2023
    Applicant: AMGEN INC.
    Inventors: Ashutosh CHAUDHRY, Wenjun OUYANG
  • INHIBITIONS OF SIRP-GAMMA FOR CANCER TREATMENT
    Publication number: 20220305081
    Abstract: Provided herein are methods of treating a subject with a tumor or cancer. In exemplary embodiments, the method comprises increasing an immune response against the tumor or cancer in the subject or increasing effector activity or reducing suppressive activity of T-cells in the subject. In exemplary embodiments, the method comprises administering to the subject a SIRP? binder, e.g., SIRP? inhibitor, in an amount effective to treat the tumor or cancer in the subject.
    Type: Application
    Filed: June 23, 2020
    Publication date: September 29, 2022
    Inventors: Ruozhen HU, Paolo MANZANILLO, Wenjun OUYANG
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20220204606
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: July 12, 2021
    Publication date: June 30, 2022
    Inventors: David P Arnott, Mercedesz Balazs, Nico Ghilardi, Austin L. Gurney, Philip E. Hass, Sarah Hymowitz, James M. Lee, Wenjun Ouyang, Melissa A. Starovasnik, Yan Wu
  • IL-22 Fc fusion proteins
    Patent number: 11332507
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: May 17, 2022
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • METHODS FOR TREATMENT OF MICROBIAL DISORDERS
    Publication number: 20210338778
    Abstract: The present invention relates to compositions and methods for treatment of microbial disorder by modulation of the host immune response. More particularly, the present invention relates to compositions that mediate an anti-microbial immune response, and methods of treating a microbial infection using such compositions.
    Type: Application
    Filed: January 29, 2021
    Publication date: November 4, 2021
    Inventors: Alexander R. ABBAS, Nico P. GHILARDI, Zora MODRUSAN, Dimitry M. DANILENKO, Frederic J. DE SAUVAGE, Wenjun OUYANG, Patricia A. VALDEZ, Yan ZHENG
  • Methods of treating acute pancreatitis using IL-22 fc fusion proteins
    Patent number: 11155591
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 26, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
  • Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins
    Patent number: 11136365
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 5, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen
  • COMBINATION OF LILRB1/2 PATHWAY INHIBITORS AND PD-1 PATHWAY INHIBITORS
    Publication number: 20210301020
    Abstract: This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 30, 2021
    Applicant: AMGEN INC.
    Inventors: Xin YU, Wenjun OUYANG, Chi-Ming Kevin LI, Jackson Graeme EGEN, Oh Kyu YOON, Ian Halsey DRIVER, Shunsuke TAKENAKA, Christy Ann THOMSON, Hongyu WANG
  • Methods for treating metabolic syndrome using IL-22 Fc fusion proteins
    Patent number: 11130791
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: September 28, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Eric Gary Stefanich, Richard Vandlen, Philip E. Hass, Xiaoting Wang
  • IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20200377585
    Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: February 6, 2020
    Publication date: December 3, 2020
    Applicant: Genentech, Inc.
    Inventors: David P. ARNOTT, Mercedesz BALAZS, Nico GHILARDI, Austin L. GURNEY, Philip E. HASS, Sarah HYMOWITZ, James M. LEE, Wenjun OUYANG, Melissa A. STAROVASNIK, Yan WU
  • Pharmaceutical compositions of IL-22 Fc fusion proteins
    Patent number: 10584155
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 10, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • Methods of accelerating or improving wound healing using IL-22 FC fusion proteins
    Patent number: 10544198
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang, Ganesh A. Kolumam, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190233491
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: September 11, 2018
    Publication date: August 1, 2019
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177390
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177388
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177386
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177387
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177389
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins
    Patent number: 10160793
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 25, 2018
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang